SCHEMBL4340656

SCHEMBL4340656

COc1c(NC(=O)[C@@H]2CCC(=O)N2)ccc2[nH]nc(-c3cc4ccccc4s3)c12

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
TNIK Q9UKE5 5/20 0.40
NTRK1 P04629 1/20 0.36
FLT3 P36888 1/20 0.36
NTRK3 Q16288 1/20 0.36
NTRK2 Q16620 1/20 0.36
PIP5K1C O60331 1/20 0.36
PARP1 P09874 2/20 0.35
SLC6A3 Q01959 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
HTT P42858 1/20 0.34
JAK2 O60674 1/20 0.33
JAK3 P52333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345589 1.00 MAPK10 (0.44) MAPK10MEN1KMT2ASMN1; SMN2SIRT2
SCHEMBL4345714 0.88 MAPK10 (0.46) MAPK10MEN1KMT2ASMN1; SMN2SIRT2
SCHEMBL4335786 0.87 MAPK10 (0.52) MAPK10SIRT2SIRT1TNIKNTRK1
SCHEMBL4346877 0.84 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2PARP1SLC6A3
SCHEMBL4346834 0.84 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2PARP1SLC6A3
SCHEMBL2867309 0.83 TNIK (0.44) MAPK10MEN1KMT2ASMN1; SMN2SIRT2
SCHEMBL2860663 0.80 MAPK10 (0.67) MAPK10MEN1KMT2ASMN1; SMN2SIRT2
SCHEMBL2858445 0.80 MAPK10 (0.67) MAPK10MEN1KMT2ASMN1; SMN2SIRT2
SCHEMBL13198269 0.79 MEN1 (0.41) MEN1KMT2ASMN1; SMN2NTRK1PARP1
SCHEMBL4329118 0.79 MEN1 (0.41) MEN1KMT2ASMN1; SMN2NTRK1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK10 29/4885MEN1 3782/4885KMT2A 2212/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK10 29/4885MEN1 3782/4885KMT2A 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.